Keyword: EuroBiotech Report
In this week's EuroBiotech Report, Boehringer scraps Alzheimer’s drug, Poxel lands Roivant deal, Santhera snags cystic fibrosis drug and more.
In our EuroBiotech roundup this week, Galmed crashes after NAFLD trial flop, DBV to file for approval and CureVac lands Gates grants.
The Swiss biotech penned a CHF 127.5 million ($138 million) deal for the human neutrophil elastase inhibitor to expand its clinical pipeline.
The deal ends Poxel’s long wait for a partner capable of running a late-phase diabetes program and starts Roivant’s expansion into metabolic diseases.
BI 409306 failed to show superiority over placebo in cognition across a midphase program that enrolled 457 patients with early signs of Alzheimer’s.
In this week's EuroBiotech Report, AstraZeneca, Sanofi ditch drugs, VCs load up on cash, J&J brings JLABS to Europe and more.
In our EuroBiotech roundup this week, Acacia shuns London for IPO, Adocia files $200M lawsuit against Lilly and Bavarian hails phase 3 success.
The 30-startup hub will supersede the JLINX incubator J&J helped to set up at its R&D site in Beerse, Belgium.
The haul makes BioDiscovery 5 the largest fund dedicated to biotechs and medical devices in Europe and tees up De Rothschild to invest in 17 firms.
The agreements stand to create investment vehicles with more than $1 billion under management and an interest in bringing British innovation to China.